Trigeminal autonomic cephalalgias: current and future treatments.
The trigeminal autonomic cephalgias include cluster headache, paroxysmal hemicrania, and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT). The evidence for the current treatment options for each of these syndromes is considered, including oxygen, sumatriptan, and verapamil in cluster headache, indomethacin in paroxysmal hemicrania, and intravenous lidocaine and lamotrigine in SUNCT. Some treatments such as topiramate have an effect in all of these, as well as in migraine and other pain syndromes. The involvement of the hypothalamus in functional imaging studies implies that this may be a substrate for targeting treatment options in the future.
Cohen
Anna S
AS
Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Matharu
Manjit S
MS
Goadsby
Peter J
PJ
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D006801:Humans; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D051303:Trigeminal Autonomic Cephalalgias / Q000188:drug therapy* / Q000517:prevention & control*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D017366:Serotonin Receptor Agonists; D014665:Vasodilator Agents